Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 15/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361331 | 1.00 | GALR3 (0.48) | GALR3HTR4DRD5KMT2AMAPT | |
| SCHEMBL917487 | 0.91 | GALR3 (0.57) | GALR3HTR4DRD5KMT2AMAPT | |
| SCHEMBL917489 | 0.91 | GALR3 (0.57) | GALR3HTR4DRD5KMT2AMAPT | |
| SCHEMBL8177516 | 0.83 | GALR3 (0.55) | GALR3HTR4DRD5KMT2AMAPT | |
| SCHEMBL5356416 | 0.78 | GALR3 (0.56) | GALR3HTR4KMT2AMAPTMEN1 | |
| SCHEMBL5356411 | 0.78 | GALR3 (0.56) | GALR3HTR4KMT2AMAPTMEN1 | |
| SCHEMBL5357195 | 0.78 | GALR3 (0.53) | GALR3HTR4KMT2AMAPTMEN1 | |
| SCHEMBL5357199 | 0.78 | GALR3 (0.53) | GALR3HTR4KMT2AMAPTMEN1 | |
| SCHEMBL8250355 | 0.76 | TTR (0.61) | GALR3HTR4KMT2AMAPTMEN1 | |
| SCHEMBL8360408 | 0.76 | GALR3 (0.48) | GALR3HTR4KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166635-B2 | 3-imino-2-indolones for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2007-01-23 | — | — | US | disclosed |
| US-20050148635-A1 | 3-imino-2-indolones for the treatment of depression and/or anxiety | SYNAPTIC PHARMACEUTICAL CORPORATION | 2005-07-07 | — | — | US | disclosed |
| US-20040082615-A1 | 3-Imino-2-indolones for the treatement of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148635-A1 | 3-imino-2-indolones for the treatment of depression and/or anxiety | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 17/4885DRD5 452/4885 |
| US-20040082615-A1 | 3-Imino-2-indolones for the treatement of depression and/or anxiety | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 13/4885DRD5 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.